Evropská unie - angličtina - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - breast neoplasms - endocrine therapy, anti-estrogens - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy., , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , in pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.,

Evropská unie - angličtina - EMA (European Medicines Agency)

ab science s.a. - masitinib mesilate - antineoplastic agents - dogs - treatment of non-resectable dog mast-cell tumours (grade 2 or 3) with confirmed mutated c-kit tyrosine-kinase receptor.

Evropská unie - angličtina - EMA (European Medicines Agency)

roche registration gmbh - erlotinib - carcinoma, non-small-cell lung; pancreatic neoplasms - antineoplastic agents - non-small cell lung cancer (nsclc)tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with egfr activating mutations and stable disease after first-line chemotherapy.tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.in patients with tumours without egfr activating mutations, tarceva is indicated when other treatment options are not considered suitable.when prescribing tarceva, factors associated with prolonged survival should be taken into account.no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with epidermal growth factor receptor (egfr)-ihc - negative tumours.pancreatic cancertarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.when prescribing tarceva, factors associated with prolonged survival should be taken into account.

Evropská unie - angličtina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - fulvestrant - breast neoplasms - endocrine therapy - fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on antiestrogen therapy.

Evropská unie - angličtina - EMA (European Medicines Agency)

advanced accelerator applications - lutetium (177lu) oxodotreotide - neuroendocrine tumors - other therapeutic radiopharmaceuticals - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep‑nets) in adults.

Izrael - angličtina - Ministry of Health

j-c health care ltd - macitentan - film coated tablets - macitentan 10 mg - macitentan - opsumit ® is an endothelin receptor antagonist (era) indicated for the treatment of pulmonary arterial hypertension (pah, who group i) to delay disease progression. disease progression included: death, initiation of intravenous (iv) or subcutaneous prostanoids or clinical worsening of pah (decreased 6-minute walk distance, worsened pah symptoms and need for additional pah treatment). opsumit also reduced hospitalization for pah.

Izrael - angličtina - Ministry of Health

j-c health care ltd - macitentan - film coated tablets - macitentan 10 mg - macitentan - opsumit ® is an endothelin receptor antagonist (era) indicated for the treatment of pulmonary arterial hypertension (pah, who group i) to delay disease progression. disease progression included: death, initiation of intravenous (iv) or subcutaneous prostanoids or clinical worsening of pah (decreased 6-minute walk distance, worsened pah symptoms and need for additional pah treatment). opsumit also reduced hospitalization for pah.

Spojené státy - angličtina - NLM (National Library of Medicine)

hcbiopharm llc - lagerstroemia speciosa leaf 1x, morinda citrifolia fruit 1x - reduces insulin resistance, restores defective insulin receptors, and maintains a normal blood sugar level* - to reduce insulin resistance - to restore defective insulin receptors - to maintain a normal blood sugar level

Evropská unie - angličtina - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - immunosuppressants - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: ethanol; benzyl alcohol; benzyl benzoate; castor oil - fulvestrant-aft is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.